# Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

> **NCT04810182** · — · COMPLETED · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 192 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Regorafenib 40 MG Oral Tablet [STIVARGA]

## Key facts

- **NCT ID:** NCT04810182
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-10
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810182, "Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04810182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*